Claritas Pharmaceuticals, Inc.

CLAZF · OTC
Analyze with AI
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating Activities
Net Income$4,210-$21,212$6,935-$31,863
Dep. & Amort.$18,014$33,329$0$0
Deferred Tax-$5,142-$11$0$0
Stock-Based Comp.$0$3$875$346
Change in WC-$5,565-$4,393$1,117-$690
Other Non-Cash-$12,042-$15,121-$13,775$26,646
Operating Cash Flow-$309-$6,483-$4,848-$5,561
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0-$10,000
Inv. Purchases$0-$8$0$0
Inv. Sales/Matur.$2$0$0$0
Other Inv. Act.$0-$180$0$0
Investing Cash Flow$2-$188$0-$10,000
Financing Activities
Debt Repay.$0$292$0$3,981
Stock Issued$0$6,184$3,233$14,577
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$295$0-$1,844$16
Financing Cash Flow$295$6,476$1,389$18,574
Forex Effect-$32$0$0$0
Net Chg. in Cash-$44-$195-$3,459$3,013
Supplemental Information
Beg. Cash$32$227$3,686$673
End Cash-$12$32$227$3,686
Free Cash Flow-$309-$6,483-$4,848-$5,561
Claritas Pharmaceuticals, Inc. (CLAZF) Financial Statements & Key Stats | AlphaPilot